Final Operational Milestone #3

We have compiled the data on our gene correction of autologous hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6, developed a clinical protocol, performed a tumor/toxicology study and submitted an IND to the FDA to seek approval for starting a phase I/II study.